A Phase 2 interventional study of ARGX-119 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by argenx. Terminated at 9 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 44th largest by enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 21 in phase 2, and was the 70th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Nura Bio · Sites in Canada, Australia, Netherlands and 1 more country
Ages 18–80
Prilenia · Sites in Canada, United States, Belgium and 10 more countries
Ages 18–80
Zydus Therapeutics Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 29 · Phase 3 23 · Phase 4 1
First in 2001; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 75 across the 72 interventional studies, 148 across the 10 observational. Of the 49 that completed or were terminated, 24 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 82 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07193953Sunnybrook Health Sciences CentreIntravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-30 |
| NCT06051123Centre hospitalier de l'Université de Montréal (CHUM)Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period when all participants will receive the same dose of ARGX-119. Participation in the study will last up to approximately 100 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive first dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
Biological: ARGX-119
Participants will receive second dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
Biological: ARGX-119
Participants will receive third dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
Biological: ARGX-119
Participants will receive placebo intravenously during the double-blinded treatment period followed by ARGX-119 in active treatment extension period
Biological: ARGX-119 · Other: Placebo
Drug pages: Adimanebart · Anti-MuSK Agonistic Monoclonal Antibody ARGX-119
Intravenous infusion of ARGX-119
Intravenous infusion of placebo
Assessment of adverse events (AEs)
Time frame: Up to week 96
Rate of change from baseline in electrophysiological muscle scan (MScan)-derived motor unit number (MUN)
Time frame: Up to week 24
Maximum observed serum concentration (Cmax) of ARGX-119
Time frame: Up to week 96
Incidence of anti-drug antibodies (ADA) against ARGX-119 in serum over time
Time frame: Up to week 96
Prevalence of anti-drug antibodies (ADA) against ARGX-119 in serum over time
Time frame: Up to week 96
Plan to share: No
Ran from Oct 2024 to primary completion in Aug 2026, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adimanebart · Anti-MuSK Agonistic Monoclonal Antibody ARGX-119
Amyotrophic Lateral Sclerosis →